MADISON, Wis. – Gentel Biosciences, a leader in proteomics profiling tools, and Eprogen, jointly announce the publication of a new book chapter featuring Gentel’s native fractionation array technology. The article can be found in the latest edition of the Springer Protocols’ Methods and Protocols Series: Methods in Molecular Biology: Protein Microarray for Disease Analysis Methods and Protocols by Humana Press. The chapter entitled, “Native Antigen Fractionation Protein Microarrays for Biomarker Discovery”, presents a detailed description of the creation and use of native protein fractionation arrays for autoantibody profiling.

“Native antigen fractionation arrays are unique in their ability to identify potential new autoantibody biomarkers based on disease associated epitopes not present in recombinant proteins,” says said Brian Liu, Ph.D., Assistant Professor of Surgery at Brigham and Women’s Hospital, and lead author on the chapter. In the chapter, Liu and colleagues used a human bladder cancer cell line as a source of native antigens to construct a fractionated whole proteome array for the purpose of comparing the autoantibody responses of individuals with interstitial cystitis and painful bladder syndrome to those of normal controls.

“This is an exciting new technology for biomarker discovery and we are pleased to make it available through our services group”, added Gentel Vice President of Technology & Business Development and chapter co-author Bryce Nelson, Ph.D. Gentel’s Proteome Partitioning service is based on native antigen fractionation array technology and supports researchers by offering custom production of native protein arrays as well as sample testing services. Researchers provide tumor, tissue, or cellular materials to Gentel for creation of arrays. These arrays can then be used for sample testing and biomarker discovery in a researcher’s lab or at Gentel.

“Proteome Partitioning combines analytical proteomics with serological assays for discovery of new clinically relevant biomarkers at the patient level. Dr. Liu’s work to develop new biomarkers and customized vaccines is one of the most exciting examples of truly personalized medicine,” stated Tim Barder, President of Eprogen, and a co-author on the chapter.

Native antigen fractionation array technology is available from Gentel’s Multiplexed Assay Services Group as Proteome Partitioning. Gentel’s services group offers multiplexed immunoassay sample testing services and custom assay development to support the development of biomarkers, therapeutics, and diagnostics from concept to clinical trial. To learn more about native antigen fractionation array technology and how it can improve your proteomics research, please visit http://www.gentelbio.com/services/proteome-partitioning.html.

About Gentel Biosciences, Inc.

Gentel delivers cost-effective, easy-to-use and reliable proteomics products and services that enable researchers to perform faster discovery, validation and screening of protein biomarkers to better understand disease and develop better therapies. Gentel’s headquarters is located in Madison, Wisconsin

About Eprogen

Eprogen is a bioanalytical chemistry company in Downers Grove, Illinois, specializing in the development of high resolution HPLC based tools, services, protocols and consumables for use in complex protein separation and analysis. The 1D and 2D all liquid-phase fractionation technologies developed work directly to produce both conventional multi-well well plate formats or printed microarray formats to serve a very useful and automated alternatives to 1D and 2D gel electrophoresis and Western blot analysis as well as a direct interface to MS and ELISA based protocols.